We provide a short research update with the latest financial estimates and valuation following IDL Biotech’s Q2’19 report. We factor in higher gross margins and slightly lower costs related to SG&A in near-term, which has a positive effect on our valuation. Our new base case amounts to SEK 3.8 per share, with a Bull and Bear Case of SEK 7.4 and 1.5 per share, respectively.